Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome


Creative Commons License

Ocuz A. , Uzunlulu M.

INTERNATIONAL HEART JOURNAL, vol.49, no.3, pp.303-311, 2008 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 3
  • Publication Date: 2008
  • Doi Number: 10.1536/ihj.49.303
  • Title of Journal : INTERNATIONAL HEART JOURNAL
  • Page Numbers: pp.303-311

Abstract

Elevated concentrations of asymmetric dimethylarginine (ADMA), all endogeneous inhibitor of nitric oxide synthase, are associated with endothelial dysfunction. Metabolic syndrome (MetS) is also a condition associated with impaired endothelial function. To test the hypothesis that lipid lowering treatment with a statin lowers ADMA levels, we investigated file effect of fluvastatin treatment on serum ADMA levels in patients with MetS.